- Home
- UPLD vs INAB Comparison
UPLD vs INAB Comparison
Compare UPLD & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPLD | INAB |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 22.9M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UPLD | INAB |
|---|---|---|
| Price | $0.88 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.50 | ★ $180.00 |
| AVG Volume (30 Days) | ★ 152.6K | 36.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.17 | ★ 43.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.88 | $0.12 |
| 52 Week High | $3.90 | $4.20 |
Technical Indicators
Market Signals| Indicator | UPLD | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 20.46 | 43.62 |
| Support Level | N/A | $1.52 |
| Resistance Level | $1.62 | $2.55 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 6.92 | 42.11 |
Price Performance
Historical ComparisonAbout UPLD Upland Software Inc.
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.